Datos finales de la Fase II que evalan REVLIMID y rituximab en pacientes con leucemia linfoctica crnica recurrente o resistente

Show Health and Fitness Publications

Thu, December 15, 2011

[ Thu, Dec 15th 2011 ]: Market Wire

New Management Changes Poise USANA for Further Growth

[ Thu, Dec 15th 2011 ]: Market Wire

Covidien meldt conference call en webcast

[ Thu, Dec 15th 2011 ]: Market Wire

Gruppo di ricerca per il linfoma negli adulti (GE .. LIMID per studio sul secondo tipo di linfoma pi c

[ Thu, Dec 15th 2011 ]: Market Wire

Covidien annuncia una teleconferenza e trasmissione web

[ Thu, Dec 15th 2011 ]: Market Wire

Arrowhead to Report Fiscal 2011 Fourth Quarter and Year-End Financial Results

[ Thu, Dec 15th 2011 ]: Market Wire

Covidien plant Ausgliederung des Unternehmensbereichs Pharmazeutika

[ Thu, Dec 15th 2011 ]: Market Wire

Covidien envisage une scission de sa branche Pharmacie

[ Thu, Dec 15th 2011 ]: Market Wire

Soligenix Initiates Next Generation Anthrax Vacci .. t Program Under Agreement With Harvard University

[ Thu, Dec 15th 2011 ]: Market Wire

SciClone Pharmaceuticals Announces Final Settlement of Stockholder Derivative Litigation

[ Thu, Dec 15th 2011 ]: Market Wire

Implant Sciences Sells Over $200,000 of Quantum S .. s Trace Detectors for Building Security in Mexico

[ Thu, Dec 15th 2011 ]: Market Wire

Importante grupo cooperativo de investigacin sobr .. elige REVLIMID para el estudio del segundo subtip

[ Thu, Dec 15th 2011 ]: Market Wire

Perceptive Informatics Completes Over 500 System .. Industry Continues to Adopt Seamless eClinical S

[ Thu, Dec 15th 2011 ]: Market Wire

Illumina Hires Laura Lauman as Vice President of Marketing

Wed, December 14, 2011

[ Wed, Dec 14th 2011 ]: Market Wire

Amgen Announces Final Results of Its Tender Offer

[ Wed, Dec 14th 2011 ]: Market Wire

Tortoise Pipeline & Energy Fund Announces Full Investment and Top Ten Holdings

[ Wed, Dec 14th 2011 ]: Market Wire

Pfizer, Cisco, Walt Disney, Research In Motion, U .. ban Outfitters and Green Mountain Coffee Roasters

[ Wed, Dec 14th 2011 ]: Market Wire

A Change in Tides - Featured Research on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA)

[ Wed, Dec 14th 2011 ]: Market Wire

St. Jude Medical annuncia il primo impianto nella .. clinica per la valutazione dalla valvola cardiac

[ Wed, Dec 14th 2011 ]: Market Wire

CytoSorbents Awarded US Army SBIR Trauma Grant

[ Wed, Dec 14th 2011 ]: Market Wire

IntegraMed America Selects Adaptive Planning

[ Wed, Dec 14th 2011 ]: Market Wire

Definitieve fase 2 gegevens van evaluatie REVLIMI .. et recidiverende of refractaire chronische lymfat

[ Wed, Dec 14th 2011 ]: Market Wire

Datos finales de la Fase II que evalan REVLIMID y .. eucemia linfoctica crnica recurrente o resistente

[ Wed, Dec 14th 2011 ]: Market Wire

Premiere Cooperative Group in Adult Lymphoma Rese .. for Study in Second Most Common Lymphoma Subtype

[ Wed, Dec 14th 2011 ]: Market Wire

Salix Pharmaceuticals Announces NDA Submission fo .. emer for the Treatment of HIV-Associated Diarrhea

[ Wed, Dec 14th 2011 ]: Market Wire

Meta-analysis of Five Clinical Trials including C .. T Study Published in American Journal of Obstetri

[ Wed, Dec 14th 2011 ]: Market Wire

REVLIMID evaluado en combinacin con rituximab com .. pacientes con leucemia linfoctica crnica no trata

[ Wed, Dec 14th 2011 ]: Market Wire

Presentados en ASH los datos de un estudio de Fas .. en pacientes con mieloma indolente de alto riesgo

[ Wed, Dec 14th 2011 ]: Market Wire

OncoSec Medical Engages The Investor Relations Group

[ Wed, Dec 14th 2011 ]: Market Wire

Rsultats dfinitifs de laessai de phase II valuant .. ez les patients atteints de leucmie lymphocytaire

[ Wed, Dec 14th 2011 ]: Market Wire

Threshold Pharmaceuticals Announces Promising Pha .. Trial Results in Patients With Advanced Leukemias

[ Wed, Dec 14th 2011 ]: Market Wire

REVLIMID a t valu en combinaison avec le Rituxima .. ntiel destin aux patients atteints de leucmie lym

Tue, December 13, 2011

[ Tue, Dec 13th 2011 ]: Market Wire

Phase III Study Evaluating REVLIMID in Patients w .. Risk Smoldering Multiple Myeloma Presented at ASH

[ Tue, Dec 13th 2011 ]: Market Wire

The Briscoe Law Firm and Powers Taylor, LLP Inves .. ife Technologies, Inc. Concerning the Sale of SYN

[ Tue, Dec 13th 2011 ]: Market Wire

REVLIMID Evaluated in Combination with Rituximab .. Patients with Treatment-Naive Chronic Lymphocytic

[ Tue, Dec 13th 2011 ]: Market Wire

ICU Medical's Tego Needlefree Connector Proves Mo .. ve Than Traditional Central Venous Catheter Locks

[ Tue, Dec 13th 2011 ]: Market Wire

The Law Firm of Levi & Korsinsky, LLP Announces I .. reaches of Fiduciary Duty by the Board of Synovis

[ Tue, Dec 13th 2011 ]: Market Wire

Pharmacyclics Announces Updated Results for BTK I .. eatment of Relapsed or Refractory Chronic Lymphoc

[ Tue, Dec 13th 2011 ]: Market Wire

Daxor Announces That the VA Medical Center in Was .. gton, D.C. Acquires BVA-100 Blood Volume Analyzer

[ Tue, Dec 13th 2011 ]: Market Wire

Rigrodsky & Long, P.A. Announces Investigation of .. ologies, Inc.as Sale to Baxter International Inc.

[ Tue, Dec 13th 2011 ]: Market Wire

Healthways to Update 2011 Financial Guidance after Market Close on December 20

[ Tue, Dec 13th 2011 ]: Market Wire

U.S. Physical Therapy to Present at the Oppenheimer 22nd Annual Healthcare Conference

[ Tue, Dec 13th 2011 ]: Market Wire

Seattle Genetics and Millennium Report Data from .. Brentuximab Vedotin) in Front-line Hodgkin Lympho

[ Tue, Dec 13th 2011 ]: Market Wire

St. Jude Medical Announces First Implant in Europ .. Studying Portico Transcatheter Aortic Heart Valve

[ Tue, Dec 13th 2011 ]: Market Wire

Die Europische Kommission erteilt Astellas Pharma .. zulassung zur Verwendung von DIFICLIRa" in der EU

[ Tue, Dec 13th 2011 ]: Market Wire

La Comisin Europea concede la autorizacin de mark .. Astellas Pharma Europe Ltd., para su uso en la UE

[ Tue, Dec 13th 2011 ]: Market Wire

PhotoMedex and Radiancy Complete Merger

[ Tue, Dec 13th 2011 ]: Market Wire

Bio-Path Holdingsa Initial Phase I Data in Leukem .. s That Its Neutral Lipid Delivery Technology Anti

[ Tue, Dec 13th 2011 ]: Market Wire

Thera Maxa" Cold and Flu Debuts in Times Square D .. ring the Height of the 2011 / 2012 Holiday Season

Datos finales de la Fase II que evalan REVLIMID y rituximab en pacientes con leucemia linfoctica crnica recurrente o resistente

//health-fitness.news-articles.net/content/2011/ .. a-linfoctica-crnica-recurrente-o-resistente.html

Published in Health and Fitness on Wednesday, December 14th 2011 at 4:47 GMT by Market Wire
^{🞛 This publication is a summary or evaluation of another publication}

BOUDRY, Suiza--([ BUSINESS WIRE ])--Celgene International Srl, filial de Celgene Corporation, (NASDAQ: CELG), ha anunciado los resultados finales de un estudio de investigacin de fase II que evaluaba la combinacin de REVLIMID (lenalidomida) y rituximab en 59 pacientes con leucemia linfoctica crnica recurrente o resistente. Los datos se han presentado en la 53 Reunin Anual de la American Society of Hematology en San Diego (California).

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.